Global Kidney Cancer & Renal Cell Carcinoma Drugs Market is Segmented By Product Type (Bevacizumab, Everolimus, Cabozantinib, Axitinib, Sorafenib, Temsirolimus, Sunitinib), By Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Online Pharmacies, and Others), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Kidney Cancer and Renal Cell Carcinoma Drugs Market Overview
The Global Kidney Cancer and Renal Cell Carcinoma Drugs Market reached USD 5.6 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 8.9 billion by 2030. The global kidney cancer and renal cell carcinoma drugs market is expected to exhibit a CAGR of 6.3% during the forecast period (2023-2030). A multidisciplinary strategy is often used to treat kidney cancer, and this method includes systemic treatments such as chemotherapy, targeted therapy, and immunotherapy.
For instance, the targeted therapy drug Sunitinib is utilized as the initial therapy for advanced renal cell carcinoma (RCC). It prevents the development of blood vessels that feed the tumor, lowering its blood supply and stops its growth.
Kidney Cancer and Renal Cell Carcinoma Drugs Market Scope
|
Metrics |
Details |
|
CAGR |
6.3% |
|
Size Available for Years |
2021-2030 |
|
Forecast Period |
2023-2030 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
Product, End-users, Distribution Channel, and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
To know more Insights – Download Sample
Kidney Cancer and Renal Cell Carcinoma Drugs Market Dynamics
The Increasing Prevalence Of Kidney Cancer Is Driving The Global Kidney Cancer And Renal Cell Carcinoma Drugs Market Growth.
Renal cancer, especially renal cell carcinoma, is becoming more common around the globe. An aging population, changing lifestyles, and new diagnostic methods have all led to an increase in kidney cancer cases being discovered and diagnosed. The market for pharmaceuticals is expanding as a result of the increase in prevalence and the increased demand for efficient treatment choices.
The kidney itself is the most frequent particular site for kidney malignancies in the UK, according to Cancer Research UK, between 2023 and 2025 and 2038 and 2040, the UK is expected to have a 15% increase in the incidence of kidney cancer. In the UK, there may be 21,900 new instances of kidney cancer annually by 2038–2040, according to predictions.
Advancements in Treatment Options Are Driving The Global Kidney Cancer And Renal Cell Carcinoma Drugs Market Growth.
Immunotherapies are medical procedures that boost the body's capacity to fight cancer. Research into the treatment of kidney cancer has increasingly centered on immunotherapy. Immune checkpoint inhibitors are a class of immunotherapy drugs that are now commonly used during the course of treatment for advanced kidney cancer patients.
A small percentage of patients with clear-cell kidney carcinoma and other, more uncommon kinds of illness get complete tumor remission while using these medications. Studies are being conducted to determine the traits of individuals or tumors that increase the likelihood that immunotherapy will be effective. Additionally, combinations of targeted treatments and immunotherapies have been approved and some are currently being investigated in clinical trials.
Side Effects Associated With Kidney Cancer Drugs Are Hampering The Global Kidney Cancer And Renal Cell Carcinoma Drugs Market Growth.
Depending on the particular treatment taken, kidney cancer medications may have a variety of adverse effects. Some common adverse effects of various therapeutic classes, including targeted treatments and immunotherapies, are used to treat kidney cancer.
Targeted treatments, such as sunitinib, pazopanib, and cabozantinib have side effects including constipation, diarrhea, or exhaustion vomiting and nauseous, decrease in appetite, elevated blood pressure hand-foot syndrome, which causes swelling, redness, or pain in the hands and feet palms, difficulties with the skin (rash, dryness, or discoloration), changing hair colors or thinning hair.
Kidney Cancer and Renal Cell Carcinoma Drugs Market Segment Analysis
The global kidney cancer and renal cell carcinoma drugs market is segmented based on product, end-users, distribution channel, and region.
The Bevacizumab Segment Is Expected To Hold A Dominant Position In The Market Over The Forecast Period.
The Bevacizumab segment accounted for the highest market stake accounting for approximately 39.3% of the kidney cancer and renal cell carcinoma drugs market in 2022. Bevacizumab (Avastin), is a targeted therapy medicine that has been used to treat renal cell carcinoma (RCC), a type of kidney cancer. Vascular endothelial growth factor (VEGF), a protein involved in the development of blood arteries that supply tumors, is the target of the monoclonal antibody bevacizumab.
Bevacizumab is frequently prescribed alongside other medications or as a component of combination therapy. Bevacizumab combined with interferon-alpha is one such combination that has shown effectiveness in the management of advanced RCC. Bevacizumab and interferon-alpha have been given FDA approval for the treatment of advanced RCC. In clinical trials, this combination therapy outperformed interferon-alpha alone in terms of progression-free survival and objective response rates.
Source: DataM Intelligence Analysis (2023)
Kidney Cancer and Renal Cell Carcinoma Drugs Market Geographical Penetration
North America Holds A Dominant Position In The Global Kidney Cancer And Renal Cell Carcinoma Drugs Market.
North America is estimated to hold around 38.7% of the total market share throughout the forecast period. Owing to the aging population in the region is increasing, the increasing prevalence of kidney cancer boost regional growth over the forecast period. According to the American Cancer Society in 2023, 81,800 new cases of kidney cancer (52,360 in men and 29,440 in women) would be detected in the United States.
In total, 14,890 people will pass away from this illness (9,920 males and 4,970 women). These figures encompass all forms of renal pelvis and kidney cancer. The majority of kidney cancer patients are elderly. The majority of persons are diagnosed between the ages of 65 and 74, with an average diagnosis age of 64. When a person is under the age of 45, kidney cancer is quite rare.
Source: DataM Intelligence Analysis (2023)
Kidney Cancer and Renal Cell Carcinoma Drugs Market Players
The major global players in the market include Roche Inc, GlaxoSmithKline Plc., Active Biotech Ab., Heidelberg Pharma AG, Inc., Bristol-Myers Squibb, Eisai, Exelixis, Novartis AG, Amgen, and Bayer AG among others.
COVID-19 Impact on Kidney Cancer and Renal Cell Carcinoma Drugs Market
Russia Ukraine Conflict Analysis
The Russia-Ukraine war may affect the kidney cancer and renal cell carcinoma drugs market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Clinical trials are essential for developing novel and effective treatments for RCC and kidney cancer. Access to novel medicines could be impacted if the conflict restricts or makes it difficult for patients and healthcare professionals to participate in these trials.
Artificial Intelligence Analysis:
Artificial intelligence (AI) is increasingly being used in the kidney cancer and renal cell carcinoma drugs market to improve various aspects of the treatment of the disease. With the aid of massive data sets, AI algorithms can advance personalized RCC detection and diagnosis in leaps and bounds toward the autonomous illness diagnosis sector. RCC is a multifaceted disease with various genetic and epigenetic changes.
By Product
- Bevacizumab
- Everolimus
- Cabozantinib
- Axitinib
- Sorafenib
- Temsirolimus
- Sunitinib
- Pazopanib
By End-users
- Hospitals
- Ambulatory Surgical Centers
- Specialty Centers
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- The U.K.
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Key Developments
- In October 2022, Health Canada approved KEYTRUDA (pembrolizumab) as a monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy or after nephrectomy plus resection of metastatic lesions.
- In August 2022, the European Commission (EC) authorized Celltrion Healthcare's Vegzelma (CT-P16) for the treatment of metastatic renal cell carcinoma and other cancers.
Why Purchase the Report?
- To visualize the global kidney cancer and renal cell carcinoma drugs market segmentation based on the product, end-user, distribution channel, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of kidney cancer and renal cell carcinoma Drugs market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global kidney cancer and renal cell carcinoma drugs market report would provide approximately 61 tables, 63 figures, and 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
